Granulocyte colony-stimulating factor produces long-term changes in gene and microRNA expression profiles in CD34+ cells from healthy donors

Haematologica

Volumn 99, Issue 2, 2014, Pages 243-251

  Báez, Alicia ^a   Martín Antonio, Beatriz ^b   Piruat, José I ^a   Prats, Concepción ^a   Álvarez Laderas, Isabe ^a   Barbado, M Victoria ^a   Carmona, Magdalena ^a   Urbano Ispizua, Álvaro ^b,c   Pérez Simón, Jose Antonio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; MICRORNA; MICRORNA 182;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; ANTIGENS, CD34; BLOOD DONORS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MICRORNAS; TIME FACTORS;

EID: 84896704960     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.086959     Document Type: Article

References (47)

1. Abrams RA, Glaubiger D, Appelbaum FR, Deisseroth AB. Result of attempted hematopoietic reconstitution using isologous peripheral blood mononuclear cells: a case report. Blood. 1980;56(3):516-20.
2. Kessinger A, Armitage JO, Landmark JD, Weisenburger DD. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol. 1986;14(3):192-6.
3. Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ. Circulating autologous stem cells collected in very early remission from acute non lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol. 1985;61(4):739-45.
4. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood. 1986;67(2):529-32.
5. Hölig K, Kramer M, Kroschinsky F, Bornhäuser M, Mengling T, Schmidt AH, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114(18):3757-63.
6. de la Rubia J, de Arriba F, Arbona C, Pascual MJ, Zamora C, Insunza A, et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica. 2008;93(5):735-40.
7. Mielcarek M, Storer B, Martin PJ, Forman SJ, Negrin RS, Flowers ME, et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood. 2012;119(11):2675-8.
8. Semerad CL, Christopher M, Liu F, Short B, Simmons PJ, Winkler I, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood. 2005;106(9):3020-7.
9. Levesque JP, Hendy J, Takamatsu Y. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol. 2002;30(5):440-9.
10. Liu F, Poursine-Laurent J, Link DC. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin-8 but not flt-3 ligand. Blood. 1997;90(7):2522-8.
11. Pruijt JF, Verzaal P, Van-os R. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. Proc Natl Acad Sci USA. 2002;99(9): 6228-33.
12. Pelus LM, Bian H, King AG. Neutrophilderived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRO beta/CXCL2 and GRObetaT /CXCL2 delta4. Blood. 2004;103 (1):110-9.
13. Levesque JP, Takamatsu Y, Nilsson SK. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001;98 (5):1289-97.
14. Doitsidou M, Reichman-Fried M, Stebler JÇ, Koprunner M, Dorries J, Dea M. Guidance of primordial germ cell migration by the chemokine SDF-1. Cell. 2002;111(5):647-59.
15. Jin P, Wang E, Ren J, Childs R, Won Shin J, Khuu H, et al. Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med. 2008;6:39.
16. Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood. 2009;114(12):2530-41.
17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66.
18. Naglera A, Korenstein-Ilanb A, Amielc A, Avivib L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol. 2004;32(1):122-30.
19. Hernández JM, Castilla C, Gutiérrez NC, Isidro IM, Delgado M, de las Rivas J, et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia. 2005;19(6):1088-91.
20. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol. 2007;117(2):68-3.
21. To LB, Haylock DN, Simmons PJ, Juttner CA. The biology and clinical uses of blood stem cells. Blood. 1997;89(7):2233-58.
22. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008;18(3):350-9.
23. Ge TT, Liang Y, Fu R, Wang GJ, Ruan EB, Qu W, et al. Expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(2):305-9.
24. Li S, Liang Z, Xu L, Zou F. MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases. Mol Cell Biochem. 2012;360(1-2):147-58.
25. Jiang L, Mao P, Song L, Wu J, Huang J, Lin C, et al. miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol. 2010;177(1):29-38.
26. Xiong Q, Zhong Q, Zhang J, Yang M, Li C, Zheng P, et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res. 2012;11(4):2078-90.
27. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-111expression. PLoS One. 2011;6(4):e19139.
28. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J Cell Mol Med. 2009; 13(1):39-53.
29. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012;228(2):204-15.
30. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011;41(2):210-20.
31. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, et al. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci USA. 2009;106(26):10746-51.
32. Chigrinova E, Mian M, Shen Y, Greiner TC, Chan WC, Vose JM, et al. Integrated profiling of diffuse large B-cell lymphoma with 7q gain. Br J Haematol. 2011;153(4):499-503.
33. Qiao Y, Ma N, Wang X, Hui Y, Li F, Xiang Y, et al. MiR-483-5p controls angiogenesis in vitro and targets serum response factor. FEBS Lett. 2011;585(19):3095-100.
34. Perazzona B, Lin H, Sun T, Wang Y, Arlinghaus R. Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects. Oncogene. 2008;27(15):2208-14.
35. Provencio M, Martín P, García V, Candia A, Sánchez AC, Bellas C. Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma. 2010;51(11):2021-30.
36. Kawamura H, Kawamura T, Kanda Y, Kobayashi T, Abo T. Extracellular ATP-stimulated macrophages produce macrophage inflammatory protein-2 which is important for neutrophil migration. Immunology. 2012;136(4):448-58.
37. Gibbs JD, Liebermann DA, Hoffman B. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene. 2008;27(1):98-106.
38. Lee SY, Yoon J, Lee MH, Jung SK, Kim DJ, Bode AM, et al. The role of heterodimeric AP-1 protein comprised of JunD and c-Fos proteins in hematopoiesis. J Biol Chem. 2012;287(37):31342-8.
39. Gibbs BF, Yasinska IM, Pchejetski D, Wyszynski RW, Sumbayev VV. Differential control of hypoxia-inducible factor 1 activity during pro-inflammatory reactions of human haematopoietic cells of myeloid lineage. Int J Biochem Cell Biol. 2012;44 (11):1739-49.
40. Ohno Y, Yasunaga S, Janmohamed S, Ohtsubo M, Saeki K, Kurogi T, et al. Hoxa9 transduction induces hematopoietic stem and progenitor cell activity through direct down-regulation of geminin protein. PLoS One. 2013;8(1):e53161.
41. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277 (19):16639-47.
42. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, et al. Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome. Br J Haematol. 2011;155(2):272-4.
43. Gough SM, Slape CI, Aplan PD. NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. Blood. 2011;118(24):6247-57.
44. Jung H, Kim MJ, Kim DO, Kim WS, Yoon SJ, Park YJ, et al. TXNIP maintains the hematopoietic cell pool by switching the function of p53 under oxidative stress. Cell Metab. 2013;18(1):75-85.
45. Park IK, Mishra A, Chandler J, Whitman SP, Marcucci G, Caligiuri MA. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood. 2013;121(11):2064-73.
46. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Martinelli G, et al. PKR is activated in MDS patients and its subcellular localization depends on disease severity. Leukemia. 2008;22(12):2267-9.
47. Chen-Deutsch X, Studzinski GP. Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1a,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance. Cell Cycle. 2012;11(7):1364-73.